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Malaria remains a major global health burden, killing hundreds of thousands annually,
especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on
Immunization (EPI)-linked malaria vaccine implementation was underway. However,
in December 2019, a novel pneumonia condition termed coronavirus disease 2019
(COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
with many clinical, epidemiological, and biological parallels to malaria, was reported in
Wuhan, China. COVID-19 is spreading rapidly, and, as of the 3rd of June, 2020, more
than 382,507 persons had died from COVID-19. Children under 5 years who suffer
high malaria-attributable mortalities are largely asymptomatic for COVID-19. Considering
that the malaria burden is highest in low-income tropical countries with little capacity
to fund malaria control and eradication programs, the fight against malaria in these
regions is likely to be hampered. Access to healthcare has generally been limited,
while malaria interventions, such as seasonal malaria chemotherapy and distribution
of insecticide-treated bed nets, have been suspended due to lockdowns. Likewise,
the repurposing of antimalarials for treatment of COVID-19 shared symptoms and the
shift in focus from the production of malaria rapid diagnostic tests (RDTs) to COVID-19
RDTs is a cause for concern in malaria-endemic regions. Children are less affected
by the COVID-19 pandemic compared to the elderly. However, due to the fears of
contracting SARS-CoV-2, the elderly who are worst affected by COVID-19 may not
take children for malaria medication, resulting in high malaria-related mortalities among
children. COVID-19 has disproportionately affected developed countries, threatening
their donation capacity. These are likely to thwart malaria control efforts in low-income
regions. Here, we present perspectives on the collateral impact of COVID-19 on malaria,
especially in Africa.
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INTRODUCTION
Malaria, caused by infection with Plasmodium species parasites,
remains a major health burden globally. In 2018, 228 million
malaria cases and 405,000 deaths were reported worldwide, with
sub-Saharan Africa bearing the greatest brunt (WHO, 2018).
The global fight against malaria was at its peak with a Phase
IV Expanded Programme on Immunization (EPI)-linkedmalaria
vaccine implementation underway in Ghana, Malawi, and Kenya
(WHO, 2020c).
In December 2019, unfortunately, a novel pneumonia
condition termed coronavirus disease 2019 (COVID-19), caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), with many epidemiological, clinical, and biological parallels
to malaria, was reported in Wuhan, China (Hoffmann et al.,
2020). Initial reports appeared local, but COVID-19 rapidly
spread into a global pandemic, as declared by The World Health
Organization (WHO) on the 11th ofMarch, 2020. As of the 3rd of
June, 2020, there weremore than 6453,781 confirmed cases in 215
countries and territories, and fatalities exceeded 382,507 (https://
www.worldometers.info/coronavirus/).
SARS-CoV-2 is the seventh member of the coronaviruses, a
group of diverse, enveloped, positive-sense, single-stranded RNA
viruses (Yan et al., 2020). SARS-CoV-2 most probably originated
from bats given a 96.2% genome nucleotide sequence identity
to a coronavirus from Rhinophus affinis bat (Zhou et al., 2020).
COVID-19 is less severe in females compared to males but more
pathogenic in older persons than youths (Cheng et al., 2020).
Children under 5 years are largely asymptomatic for COVID-
19, but they suffer high rates of malaria-attributable mortalities
(WHO, 2014; Dhochak et al., 2020).
Considering that the malaria burden is highest in most low-
income countries with little capacity to fund malaria control
and eradication programs (Haakenstad et al., 2019), the fight
against malaria in these regions is likely to be impacted
negatively by the COVID-19 pandemic. COVID-19 at the time of
writing this perspective has been disproportionately affecting the
developed countries. Consequently, these countries that mostly
fund malaria control and interventions may devote disease
control resources inwards, and this could jeopardize resources for
malaria control efforts in the low-income regions.
Here, we present our views on the potential collateral impact
of COVID-19 on malaria and the likely implications of COVID-
19 pandemic on malaria, especially in Africa.
SARS-CoV-2 RECEPTOR AND MALARIA
SEVERITY
SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a
receptor for entry into the human cells (Yan et al., 2020), leading
to the downregulation of ACE2 in infected persons (Sommerstein
et al., 2020). ACE is characterized by a genetic deletion/insertion
(D/I) polymorphism, which alters the concentration of ACE
I and D allele, leading to reduced expression of ACE2. Low
D allele frequencies have been reported in some countries
affected by the pandemic, such as China and Korea (Delanghe
et al., 2020). Regarding malaria, a study in India previously
associated the D allele of ACE D/I polymorphism with malaria
(Dhangadamajhi et al., 2010). Notably, the D allele of ACE
D/I polymorphism increases angiotensin II. Another ACE2
polymorphism (C1173T substitution) also increases angiotensin
II (Dhangadamajhi et al., 2010). Furthermore, analysis of
persons of African descent reported several ACE1 and ACE2
polymorphisms. These polymorphisms increase angiotensin II,
thereby conferring protection against severe malaria in children
(Gallego-Delgado and Rodriguez, 2014). Angiotensin II has
been shown to decrease P. falciparum invasion of human
erythrocytes in a dose-dependent manner (Saraiva et al., 2011).
Since geographical variations exist for ACE D/I polymorphism
(Saab et al., 2007), determining the frequency and distribution
of D allele and other polymorphisms in African populations
is warranted to forecast the severity of infections with both
pathogens toward defining appropriate intervention approaches
and strategies to mitigate severe disease and deaths.
REPURPOSING ANTIMALARIALS FOR
TREATMENT OF COVID-19
Artemisinin combination therapy (ACT) is the current
antimalarial regime used in most endemic countries. However,
emerging artemisinin resistance has been reported (Noedl et al.,
2008; Dondorp et al., 2009). Recently, Madagascar reported a
tonic of Artemisia annua, a plant that contains artemisinin, as a
potential cure for SARS-CoV-2 (Finnan, 2020). The plant extract
is likely to be officially or illicitely adopted for COVID-19 therapy
by many countries in a desperate attempt to avert COVID-19-
related deaths despite the WHO warning against its use without
appropriate scientific approval. The WHO also discourages
the use of the artemisia herb against malaria (WHO, 2012),
though alternative medicine and pharmaceutical industries
are likely to exploit the plant for SARS-CoV-2 treatment. Any
widespread use of artemisia for SARS-CoV-2 infections will
likely potentiate the development of ACT resistance, especially
in Africa where malaria burden remains highest. This will spell
doom for malaria elimination plans across African countries and
other malaria-prone regions, as artemisinin monotherapy will
drive resistance development to the main first-line malaria drugs,
artemisinin-based combination therapy. Resistance to most of
the combination partners in ACTs (Amodiaquine, Lumefantrine,
mefloquine, and Sulphadoxine-pyrimethamine) has been well-
demonstrated already (Sibley et al., 2001; Picot et al., 2009).
Whereas, saving the world from COVID-19 using artemisia is
a noble course, its ramifications on the malaria burden should
therefore be of significant global health relevance. This calls for
continuous enrichment of the antimalaria armamentarium with
alternative drugs to avert eminent malaria catastrophe.
Moreover, antimalarials like chloroquine and
hydroxychloroquine are being used for the management of
SARS-CoV-2 against the advice of the WHO (Principi and
Esposito, 2020). However, recently, a study suggested that
chloroquine or hydroxychloroquine might be harmful in
hospitalized COVID-19 patients (Funck-Brentano and Salem,
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2020). Although the use of chloroquine against malaria parasites
had been officially discontinued in most endemic areas owing to
resistant parasites, recent studies have hinted at their possible
reintroduction for malaria treatment (Mwanza et al., 2016;
Bwire et al., 2020). The use of chloroquine and its derivatives
in COVID-19 treatment is likely to facilitate the rebound of
chloroquine-resistant malaria parasites. This will hinder the
possible use of chloroquine and its derivatives in the fight against
malaria in the future and thus further dampen the prospects of




PRODUCTION TO COVID-19 RDTs
There is evidence that companies such as SD Bioline are shifting
their mRDT production focus and repurposing the production
pipelines to COVID-19 RDTs (WHO, 2020a). RDTs are the
most widely used diagnostic tools for malaria. Therefore, the
shortage of mRDTs as a direct result of these actions is eminent
and will potentially jeopardize the WHO’s test, treat, and track
policy for malaria control. It is also feared that the shortage
of mRDTs may result in presumptive treatment of malaria
fever with associated cost implications and increased risk of
antimalarial drug resistance. Overall, these actions (or inactions)
might lead to an increase in malaria-attributable morbidity and
mortality in the WHO Africa Region, which accounted for an
estimated 93% of the global malaria cases and 94% of malaria
deaths in 2018.
FIGHTING COVID-19 AT THE EXPENSE OF
MALARIA: IS THE RISK INEVITABLE?
The world is fully focusing on COVID-19 at the expense
of other endemic diseases, such as malaria, that also have
high rates of mortality, especially in low-income countries.
For instance, there was an outbreak of malaria in Zimbabwe,
resulting in at least 131 deaths during the period of SARS-CoV-2
lockdown (Global development, 2020). Furthermore, Cameroon
reported a substantial upsurge in malaria cases and deaths
during the COVID-19 pandemic (Kindzeka, 2020). Reportedly,
the malaria deaths in Zimbabwe and Cameroon were attributed
to the shortage of malaria drugs and lack of access to medical
facilities. This trend is likely to be replicated in other African
and Asian countries with high malaria burden. Indeed, the
WHO recently warned that the malaria mortalities in sub-
Saharan Africa could double to 769,000 in 2020 following
the disruptions of malaria control efforts by the COVID-19
pandemic (WHO, 2020d). In view of this, the WHO is calling
for attention toward malaria interventions while responding
to the pandemic to avoid the unintended consequences of
SARS-CoV-2 on malaria in Africa (WHO, 2020b). One way
to mitigate this loss of attention to malaria is to include
both COVID-19 and malaria diagnoses in cases of fever. The
expansion of COVID-19 serological surveys could also be
complemented with survey for malaria to determine any patterns
in co-transmission.
DIFFERENTIAL SUSCEPTIBILITY TO
COVID-19 AND MALARIA WITH AGE
Most of the current evidence shows that SARS-CoV-2 is less
pathogenic in young children, but contrastingly, young children
are worst hit by malaria. The exact opposite is true for the adult
population especially the elderly who are more likely to develop
severe COVID-19 rather than malaria. Although the molecular
basis of how COVID-19 could affect the malaria burden
among children is not well-understood, the socio-economic
and behavioral changes that come with the closure of national
borders, population lockdowns, the concomitant collapse of
small businesses, and financial stress imposed on families,
particularly in rural populations, may indirectly affect household
response to malaria and increase malaria burden in children.
Indeed, SARS-CoV-2 has adversely affected people’s health-
seeking behavior. In general, people are hesitant to attend health
care facilities due to fears of contracting COVID-19. This could
affect the response of parents and caregivers in seeking remedial
care for children with fevers that could be due to malaria. It
is likely for example that grandparents who hitherto will take
their grandchildren for medical care against malarial fever may
hold back as they are more likely to die of COVID-19 infection
and are advised to stay at home. These changes in health-
seeking behavior may negatively impact malaria preventive
measures and case management, thereby ultimately leading to
an increase in malaria home management, which could, in turn,
lead to more severe malaria and deaths from late reporting to
health facilities.
SHARED SYMPTOMS BETWEEN MALARIA
AND COVID-19: SHOULD WE WORRY?
The common clinical symptoms of SARS-CoV-2 infection, such
as headaches, body aches, fatigue, and fever, are also applicable
to malaria infections. Moreover, some malaria and SARS-CoV-2-
infected individuals remain asymptomatic and undiagnosed and
continuously spread the respective pathogens (Chanda-Kapata
et al., 2020). The effect of Plasmodium species and SARS-CoV-2
coinfection on the immune response is not fully appreciated.
SARS-CoV-2 and P. falciparum infections cause chronic
inflammation (Ademolue et al., 2017; Fu et al., 2020), which could
trigger cancers and other chronic diseases (Hattori and Ushijima,
2016). Further studies are therefore needed to understand
the interactions between these pathogens, host immune
responses, and disease sequelae in co-infected communities
in Africa.
CONCLUSIONS AND WAY FORWARD
SARS-CoV-2 and other infectious pathogens that may emerge
later are likely to impact the global economy and health, in
unmatched proportions, particularly for weak and vulnerable
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economies and public health systems in Africa. Increased
continental disease surveillance and relevant research are
required to understand the implications of the current COVID-
19 pandemic on other endemic infectious diseases in Africa. The
Africa Center for Disease Control must use its leverage within the
African Union to encourage the allocation of funds by member
states for disease surveillance, local scientific research, and
interventions.We have highlighted the potential impact of SARS-
CoV-2 infection on malaria, particularly in Africa. Repurposing
of antimalarials and the development of diagnostics for COVID-
19 must be handled in a manner that does not jeopardize the
gains made in controlling malaria and other endemic diseases.
More concerted efforts are required to concurrently monitor the
two diseases. Particularly, malaria diagnosis could be coupled to
the COVID-19 screening and testing of suspected or confirmed
COVID-19 patients to avoid misdiagnosis and enable easy
management. Neglecting malaria in favor of COVID-19 could
prove catastrophic for global health, particularly in Africa.
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